Advances in immune-checkpoint inhibitors for the treatment of extensive-stage small cell lung cancer
Objective Small cell lung cancer(SCLC),which accounts for approximately 15%of lung cancer cases,is one of the most difficult-to-treat diseases due to its rapid growth,high malignancy,and early distant metastasis.After decades of research,the prognosis of patients with extensive-stage small cell lung cancer(ES-SCLC)remains poor.In recent years,the emergence of immune-checkpoint inhibitors(ICIs)has changed the treatment landscape of ES-SCLC.Currently,guidelines recommend ICIs in combination with platinum-based double chemotherapy for the first-line treatment of ES-SCLC.However,the system of ICIs for the treatment of ES-SCLC is not yet mature,and the exploration of combination immunotherapies is still ongoing.This paper summarizes the current status and advances of ICIs in the treatment of ES-SCLC,and provides ideas for exploring the optimal immunotherapy modalities of ES-SCLC.
Extensive-stage small cell lung cancerImmunotherapyImmune-checkpoint inhibitorsClinical develop-ment
NETL
NSTL
万方数据
